NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for serious central nervous system disorders, including suicidal depression, PTSD, chronic pain, and schizophrenia. The company operates through NeuroRx, its research and development subsidiary, and HOPE Therapeutics, its clinical care delivery subsidiary, which is intended to own and operate psychiatric treatment clinics.

−1 318,7 %

58,8 %

−2 336,5 %

0.31

— NRX Pharmaceuticals, Inc.
	%
Drug development	20% Clinical-stage development of NMDA-targeted therapies such as NRX-101 and NRX-100.
Clinical care delivery	50% Ownership and operation of psychiatric clinics through HOPE Therapeutics.
Interventional psychiatry services	20% Treatment programs using TMS, ketamine, and related neuromodulatory approaches.
Medication management and digital support	10% Ancillary psychiatric care services and patient monitoring tools.

NRx sells to physicians, clinics, and healthcare organizations that treat patients with severe psychiatric and...

Psychiatrists and interventional psychiatry physiciansprimary
They prescribe NRX-101/NRX-100 and use TMS-based protocols for severe depression and related disorders.
Psychiatric clinics and care networksprimary
They buy HOPE clinic services, treatment workflows, and neuromodulation-based care delivery.
Patients with severe CNS disordersprimary
They receive clinic-based treatment for suicidal depression, PTSD, chronic pain, and schizophrenia.
Future pharmaceutical distributors and prescriberssecondary
They represent the eventual commercial channel for approved NRX-101 and NRX-100 products.

NRx is headquartered in the United States and its reported business activity is centered on U.S...

•Headquartered in the United States
•Drug development and regulatory activity are U.S.-focused
•HOPE clinic expansion is centered on U.S. markets
•Florida is an early operating and partnership market
•U.S. FDA approval is central to future commercialization

NRx is building a two-part model: advance NMDA-targeted drug candidates through FDA review while also creating a...

Regulatory advancement of NRX-101 and NRX-100short-term

FDA approval is the main path to product commercialization and value creation.

Expand HOPE clinic footprintshort-term

Clinic ownership creates service revenue and a channel for treatment protocols.

Build outcomes-based interventional psychiatry networkmedium-term

Clinical data and protocol standardization can support physician adoption and differentiation.

NRx depends on successful FDA review, clinical validation, and execution of acquisitions and clinic integrations, all...

high

Regulatory approval may be delayed or denied

NRX-101 and NRX-100 require FDA acceptance and approval before broad commercialization.

Scope: Drug pipeline
Materiality: high

high

Acquisition and integration failures

HOPE growth depends on closing and integrating clinic acquisitions and partnerships.

Scope: HOPE Therapeutics
Materiality: high

high

Clinical efficacy and safety uncertainty

Psychiatric drug development depends on trial outcomes and tolerability in high-risk patients.

Scope: NRX-101, NRX-100
Materiality: high

medium

Reimbursement and physician adoption risk

Clinic services and TMS-based protocols require payer support and provider acceptance.

Scope: Interventional psychiatry services
Materiality: medium

Stock-based compensation

Employee and director awards

Warrant valuation

Equity-linked instruments

Convertible notes payable

Liability measurement

Acquisition accounting and impairment

HOPE acquisitions

Royalty and milestone obligations

NRX-101 commercialization

: 29.4.2026

NRX Pharmaceuticals, Inc.

Regulatory approval may be delayed or denied

Acquisition and integration failures

Clinical efficacy and safety uncertainty

Reimbursement and physician adoption risk

Neuraxis, INC

Assertio Holdings, Inc.

CNBX Pharmaceuticals Inc.

Nurix Therapeutics, Inc.

Scilex Holding Co

NEUROCRINE BIOSCIENCES INC